Skip to search formSkip to main contentSkip to account menu

Refractory Hodgkin Lymphoma

Known as: Refractory Hodgkin's Disease, Refractory Hodgkin's Lymphoma 
Hodgkin lymphoma resistant to treatment
National Institutes of Health

Related topics

Related topics

19 relations
Atypical lymphocyteDHAP RegimenESHAP regimenEVAP regimen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
EP-1246: Radiotherapy after autologous stem cell transplant in recurrent or refractory hodgkin's lymphoma
2017
2017
PD-1 blockade using nobilvir in refractory Hodgkin's lymphoma
The present disclosure provides a method of treating Hodgkin's lymphoma in a subject, comprising nobiludum, a PD-1 blocking… 
2015
2015
Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience.
BACKGROUND The treatment of patients with relapsed or refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) remains… 
2015
2015
[Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
OBJECTIVE To investigate the efficacy and safety of Rituximab combined with second line regimen for treatment of relapsed and… 
2006
2006
Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory hodgkin lymphoma (HL)
2000
2000
Efficacy of a bcnu-based high dose conditioning regimen (CBVi) followed by autologous hematopoietic stem cell transplantation (hsct) in relapsed or refractory hodgkin's disease (HD)
1995
1995
769 High dose therapy and autologous bone marrow transplantation for relapsed or refractory hodgkin's disease: The impact of total body irradiation and involved field radiation therapy
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)